Search

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. announced that it has entered into a strategic collaboration with Klinge Biopharma GmbH (Klinge) and Formycon AG for the [...]

Global Banking News-December 4, 2024-Teva's AJOVY shows promise in paediatric migraine prevention (C)2024 ENPublishing - http://www.enpublishing.co.uk Israel-based pharmaceutical company Teva Pharmaceutical Industries Ltd (NYSE:TEVA) (TASE:TEVA) on Wednesday reported positive results [...]

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, revealing differences between TD patients with a [...]

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, on September 20 presented data informing clinical strategies for switching patients to UZEDY, an extended-release injectable suspension of risperidone for subcutaneous [...]

Global Banking News-October 8, 2024-Teva's Prolia biosimilar candidate accepted for review by FDA and EMA (C)2024 ENPublishing - http://www.enpublishing.co.uk Israel-based pharmaceutical company Teva Pharmaceutical Industries Ltd (NYSE:TEVA) (TASE:TEVA) on Tuesday [...]

Teva Pharmaceutical Industries Ltd., a global pharmaceutical leader, announced that a new analysis from the European cohort of the RIM-TD open-label extension (OLE) study revealed that deutetrabenazine treatment of patients [...]

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced new efficacy, safety and tolerability results for Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study, or SOLARIS, trial evaluating TEV-'749 in [...]

Teva Pharmaceuticals announced during the 22nd Annual Global Healthcare Conference held yesterday that confidence interval 99% of the targeted injections for submission have been performed. Teva also confirmed that the [...]

Global Banking News-August 22, 2024-PureTech Health appoints new independent director to board (C)2024 ENPublishing - http://www.enpublishing.co.uk PureTech Health plc (Nasdaq:PRTC)(LSE:PRTC) announced on Thursday the appointment of Michele Holcomb, PhD, as [...]

2024 AUG 3 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in kinase inhibitors. According to news reporting from [...]

Hims & Hers Health, a health and wellness platform, reported the appointment of Kare Schultz to the company's Board of Directors. According to a release, Kare Schultz brings a unique [...]

Global Banking News-July 25, 2024-Teva, Sanofi accelerate inflammatory bowel disease drug trial (C)2024 ENPublishing - http://www.enpublishing.co.uk Teva Pharmaceuticals, a US affiliate of Israel-based pharmaceutical company Teva Pharmaceutical Industries Ltd (NYSE:TEVA) [...]

Fremanezumab appears to be an effective therapy for preventing episodic migraine in children and adolescent patients, according to results from the phase 3 SPACE study. The randomized, double-blind, placebo-controlled, parallel-group [...]

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, reported the launch of an authorized generic of Victoza1 (liraglutide injection 1.8mg), in the U.S. 'By launching an authorized generic for [...]

Teva Pharmaceutical Industries announced that it has entered an agreement with the Israel Tax Authority, ITA, resolving all pending litigation with respect to taxes payable for the Company's taxable years [...]

Teva Pharmaceuticals announced the launch of an authorized generic of Victoza, in the United States. 'By launching an authorized generic for Victoza, we are providing patients with type 2 diabetes [...]

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, reinforcing that TD has a wide-reaching, multidimensional [...]

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the U.S. Food and Drug Administration has approved AUSTEDO XR as a one pill, once-daily treatment option, now [...]

Global Banking News-May 21, 2024-Teva and Alvotech launch SIMLANDI biosimilar in the US (C)2024 ENPublishing - http://www.enpublishing.co.uk Biotech company Alvotech S.A. (NASDAQ:ALVO) and Teva Pharmaceuticals, a US affiliate of Israel-based [...]

Teva Pharmaceuticals (TEVA) and Alvotech (ALVO), 'announced the availability of SIMLANDI injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic [...]

Global Banking News-May 8, 2024-Teva and Medincell report positive Phase 3 results for TEV-'749 in schizophrenia (C)2024 ENPublishing - http://www.enpublishing.co.uk Teva Pharmaceuticals, a US affiliate of Israel-based pharmaceutical company Teva [...]

Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical (TEVA), disclosed that under the recently announced U.S. strategic partnership agreement, Alvotech will manufacture its high-concentration interchangeable biosimilar to [...]

Global Banking News-April 30, 2024-Alvotech partners with Quallent for high-concentration biosimilar (C)2024 ENPublishing - http://www.enpublishing.co.uk Biotech company Alvotech S.A. (NASDAQ:ALVO) and Teva Pharmaceuticals, a US affiliate of Israel-based pharmaceutical company [...]

Global Banking News-April 19, 2024-Alvotech and Teva forge US partnership for Humira biosimilar access (C)2024 ENPublishing - http://www.enpublishing.co.uk Global biotech company specializing in biosimilar medicines Alvotech (NASDAQ:ALVO) announced on Friday [...]

Alvotech (ALVO) announced today a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. market, the newly FDA approved high-concentration interchangeable biosimilar to Humira. [...]